Immuneering touts Phase 3 trial as FDA clears new pancreatic cancer drug

August 26, 2026 5:16 PM

Immuneering Corporation (Nasdaq: IMRX) responded to the FDA's approval of a new second-line treatment for metastatic pancreatic cancer, reiterating its ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found